From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA grants Breakthrough Therapy to sickle cell treatment crizanlizumab

from MD Magazine

The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to the investigational drug crizanlizumab for the prevention of vaso-occlusive crises in patients with sickle cell disease. Crizanlizumab, an anti-P-selectin monoclonal antibody, reduces VOCs by binding to P-selectin on platelets and endothelium in blood vessels, inhibiting interactions between cells. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063